Remedent, Inc. (REMI)
OTCMKTS
· Delayed Price · Currency is USD
0.0100
0.00 (0.00%)
At close: Jun 30, 2025
Remedent Revenue
In the fiscal year ending March 31, 2023, Remedent had annual revenue of 46.11K EUR, down -88.53%. Remedent had revenue of -459.56K in the quarter ending March 31, 2021, a decrease of -11.74%.
Revenue
46.11K EUR
Revenue Growth
-94.86%
P/S Ratio
3.85
Revenue / Employee
15.37K EUR
Employees
3
Market Cap
192.73K USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 46.11K | -355.79K | -88.53% |
Mar 31, 2022 | 401.91K | 112.97K | 39.10% |
Mar 31, 2021 | 288.94K | 68.77K | 31.23% |
Mar 31, 2020 | 220.17K | -1.21M | -84.59% |
Mar 31, 2019 | 1.43M | -762.54K | -34.80% |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Mar 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 84.04M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Remedent News
- 4 years ago - Remedent, Inc. Files Form 15 to Suspend SEC Exchange Act Registration and Applies to Qualify for OTC Markets Alternative Reporting Standard for Pink Sheet Companies - GlobeNewsWire